ESR1 and cancer: While the supplementation of exogenous estrogen and phytoestrogens has been implicated in reducing the severity of menopause symptoms, the overaction of ER-α leads to an increased risk of cancer, whereas the activation of ER-β suppresses the proliferation of these tumor cells[22–23].